HERAN Partners co-leads the GBP 6,5m financing round of Hypervision Surgical to support the further development and commercial roll-out of their Hyperspectral Imaging platform
HERAN Partners is pleased to announce its investment in Hypervision Surgical, a London-based venture which aims to revolutionise the outcomes of surgical interventions by augmenting a surgeon’s ability to assess the status of tissue, to distinguish between different tissue types, and to discriminate healthy from unhealthy tissue. This investment endorses HERAN’s European expansion and broadening of the syndication partner network.
Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising GBP 6,5m. By harnessing AI and clinical edge computing, this King’s College London spin-out aims to revolutionise surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties.
"We are incredibly excited about the transformative potential of our Hyperspectral Intelligence platform," said Michael Ebner, CEO and co-founder of Hypervision Surgical. "Imagine a complex tumour surgery where surgeons can rely on precise measurements and tissue property information to distinguish between healthy and unhealthy tissue. Our technology makes the invisible visible, empowering surgeons to make confident decisions with enhanced precision and ultimately improving patient outcomes."
The funding round was led by a syndicate of highly experienced European and American HealthTech investors, including HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures, the corporate venture arm of the optical systems multinational ZEISS Group – a global technology leader operating in the fields of optics and optoelectronics.
Raf Roelands, Investment Director at HERAN Partners, stated, "Hypervision Surgical's hardware-agnostic solution has the potential to redefine the standard of care in surgical imaging across various procedures, from open to minimally invasive, robotics, and microscopic surgeries."
Daniel Dillinger, Investment Manager at Redalpine, emphasised, “Hypervision Surgical’s objective tissue characterisation and analytics platform is uniquely positioned to drive surgical decision-making and address critical unmet needs in the growing field of minimally invasive surgery, which sees nearly 200 million procedures annually.”
Iñaki Berenguer, Founding Partner at LifeX Ventures, highlighted the potential impact, stating, "The innovation in AI-powered vision systems, with simplified deployment in hospitals, holds the key to significantly improving the lives of millions of patients undergoing critical surgeries. Hypervision Surgical has the necessary ingredients to lead in this category."
In conjunction with the funding announcement, Hypervision Surgical is delighted to welcome Martin Frost CBE, Founder and former CEO of CMR Surgical, to its board of directors. Frost has an extensive track record as a technology executive and director, having spent decades building and leading multiple companies, including through initial public offerings. Notably, he founded CMR Surgical in 2014 and swiftly scaled it into a globally recognised unicorn in the field of surgical robotics. In recognition of his exceptional contributions to Robotics and the British Industry, Frost was honoured with a CBE.
"We are thrilled to have Martin Frost join our board of directors," said Michael Ebner. "His unparalleled expertise in building and scaling surgical technology ventures will be invaluable as we navigate the next phase of Hypervision Surgical's growth and commercialisation efforts."
The newly secured funding will accelerate the development of Hypervision Surgical's cutting-edge vision technology and be used to attain regulatory clearance in the United States and Europe. The company will expand collaborations with leading surgeons, renowned surgical centres, and strategic industry partners on both sides of the Atlantic to ensure a successful market launch and smooth integration into clinical practice. Additionally, the completion of UK clinical evaluation studies on colorectal and neurosurgery in the coming year will further enhance its evidence base.
About Hypervision Surgical
Hypervision Surgical Ltd, a spin-out from King's College London, is developing an intraoperative imaging system that seamlessly integrates into the surgical workflow for real-time tissue characterisation. Their goal is to revolutionise surgical outcomes through advanced computer-assisted analysis, enhancing precision and patient safety. For more information, visit https://hypervisionsurgical.com/